Inhaled Insulin: Overcoming Barriers to Insulin Therapy?

Long-term Efficacy

Although there are no long-term studies on Exubera®, at least three open label extension studies and one meta-analysis of these studies have been published as abstracts.[30-33] Data from these studies suggest that the efficacy of inhaled insulin is maintained up to four years. In an open label extension study, patients with type 1 diabetes, insulin-requiring type 2 diabetes and type 2 diabetes inadequately controlled on oral therapies were offered continued inhaled insulin therapy (Exubera®) after completion of the initial three-month trial. At the end of four years, the reduction in HbA1C was slightly lower than at baseline (8.23% vs. 8.71%).[30] In another two-year extension of a six-month efficacy study involving 304 type 2 diabetes patients, inhaled insulin (Exubera®) was compared with oral therapies. Patients treated with inhaled insulin had greater reductions in HbA1C (7.7% vs. 8.1%) that were maintained up to two years[31] ( table 2 ).   Printer- Friendly Email This

Br J Diabetes Vasc Dis.  2006;6(3):103-108.  ©2006 Sherborne Gibbs Ltd.
This is a part of article Inhaled Insulin: Overcoming Barriers to Insulin Therapy? Taken from "Buy Avandia Rosiglitazone" Information Blog